Holen Sie sich die Stockscreener-App
8.61
0.70%
0.06
Handel nachbörslich:
8.33
-0.28
-3.25%
Schlusskurs vom Vortag:
$8.55
Offen:
$8.54
24-Stunden-Volumen:
424.06K
Relative Volume:
0.41
Marktkapitalisierung:
$453.04M
Einnahmen:
$27.46M
Nettoeinkommen (Verlust:
$-46.05M
KGV:
-9.1596
EPS:
-0.94
Netto-Cashflow:
$-33.83M
1W Leistung:
+4.24%
1M Leistung:
+19.58%
6M Leistung:
+79.00%
1J Leistung:
+85.96%
1-Tages-Spanne:
$8.26
$8.65
1-Wochen-Bereich:
$8.11
$8.67
52-Wochen-Spanne:
$3.89
$8.95
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Firmenname
Zevra Therapeutics Inc
Sektor
Branche
Telefon
(321) 939-3416
Adresse
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-17 | Eingeleitet | Maxim Group | Buy |
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Zevra Therapeutics (ZVRA) to Release Earnings on Tuesday - MarketBeat
Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Zevra Therapeutics Inc - GuruFocus.com
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024 - The Manila Times
Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline - Yahoo Finance
How To Trade (ZVRA) - Stock Traders Daily
Will Zevra Gallop Or Saunter In Q3? - RTTNews
Objective long/short (ZVRA) Report - Stock Traders Daily
Sanctuary Advisors LLC Makes New $474,000 Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra therapeutics director Corey Watton buys $3,957 in stock - Investing.com India
Zevra therapeutics director Corey Watton buys $3,957 in stock By Investing.com - Investing.com Australia
Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN
Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Price Target at $20.83 - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Up 25.7% in September - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat
A company insider recently bought 2,000 shares of Zevra Therapeutics Inc [ZVRA]. Should You Buy? - Knox Daily
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - The Manila Times
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented - EIN News
Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - GuruFocus.com
Zevra Therapeutics Inc (ZVRA) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders - The Manila Times
When Will Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Breakeven? - Simply Wall St
Guggenheim Begins Coverage on Zevra Therapeutics (NASDAQ:ZVRA) - MarketBeat
(ZVRA) Proactive Strategies - Stock Traders Daily
HC Wainwright Comments on Zevra Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ZVRA) - Defense World
HC Wainwright Weighs in on Zevra Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Brokers Issue Forecasts for Zevra Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics' SWOT analysis: rare disease focus drives stock potential By Investing.com - Investing.com South Africa
Zevra Therapeutics shares keep Buy rating on FDA approval By Investing.com - Investing.com Canada
Zevra Therapeutics' SWOT analysis: rare disease focus drives stock potential - Investing.com India
Zevra Therapeutics shares keep Buy rating on FDA approval - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
The week in pharma: action, reaction and insight – week to September 27 | Biotechnology | The Pharmaletter - The Pharma Letter
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) to Post FY2024 Earnings of ($1.57) Per Share, Roth Capital Forecasts - MarketBeat
Zevra to Present Phase 2 Data on KP1077 for Idiopathic Hypersomnia - Sleep Review
(ZVRA) Long Term Investment Analysis - Stock Traders Daily
Investors in Zevra Therapeutics (NASDAQ:ZVRA) have seen decent returns of 67% over the past year - Yahoo Finance
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last? - Yahoo Finance
JMP Securities sees Zevra stock upside with key Niemann-Pick therapy approval - Investing.com Australia
Zevra Therapeutics stock target lifted, keeps buy on FDA drug approval - Investing.com Australia
Take your (Niemann-) Pick: Intrabio’s Aqneursa wins FDA nod - BioWorld Online
US FDA approves IntraBio's drug for rare genetic disease - Reuters
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock - Benzinga
Zevra Therapeutics share price target lifted, buy rating held on FDA approval - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by Analysts at JMP Securities - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Increased to $21.00 by Analysts at Roth Mkm - MarketBeat
Zevra Therapeutics Mixed Q2 Results: Details - MSN
Zevra Therapeutics price target raised to $25 from $18 at Maxim - TipRanks
Finanzdaten der Zevra Therapeutics Inc-Aktie (ZVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zevra Therapeutics Inc-Aktie (ZVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Clifton R. LaDuane | CFO & Treasurer |
Jul 17 '24 |
Buy |
6.77 |
2,000 |
13,540 |
18,469 |
| Anderson Thomas | Director |
Jul 16 '24 |
Buy |
6.81 |
10,000 |
68,065 |
20,000 |
| Bode John B | Director |
Jul 12 '24 |
Buy |
5.87 |
10,000 |
58,661 |
30,000 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):